Skip to main content

Genitourinary Syndrome of Menopause (GSM)

Genitourinary syndrome of menopause (GSM) is a chronic, progressive condition resulting from declining estrogen and androgen levels during the menopausal transition, affecting the vulva, vagina, urethra, and bladder. It affects approximately 27–84% of postmenopausal women and is widely underdiagnosed and undertreated.[1][2][3] The term was introduced in 2014 by the International Society for the Study of Women's Sexual Health and the North American Menopause Society to replace the narrower term "vulvovaginal atrophy."[4] For urogynecologists and pelvic reconstructive surgeons, GSM is a foundational diagnosis — urinary symptoms attributed to recurrent UTI, urgency incontinence, or bladder dysfunction may in fact represent genitourinary atrophy, and local estrogen may treat coexisting GSM around pelvic floor procedures. The 2026 EVA trial reported subjective benefit without improved anatomical or composite surgical success; see the POP evidence summary and perioperative estrogen evidence.

Definition and terminology​

GSM encompasses the full constellation of genital, sexual, and urinary symptoms associated with hypoestrogenism — not limited to vaginal atrophy alone. Unlike vasomotor symptoms, which may resolve over time, GSM symptoms are typically progressive and unlikely to resolve spontaneously without treatment.[5][2]

Similar genitourinary symptoms can occur in premenopausal hypoestrogenic states, including postpartum and lactation, hypothalamic amenorrhea, and use of antiestrogenic medications such as aromatase inhibitors, GnRH agonists, and tamoxifen.[6][4]

Pathophysiology​

The underlying mechanism is estrogen deficiency leading to anatomic and physiologic changes throughout the genitourinary tract:[6][7][9]

  • Vaginal epithelium becomes thin, pale, and less elastic, with decreased perfusion and loss of rugae.
  • Vaginal pH rises above 4.5 (from the normal premenopausal range of 3.5–4.5), creating an environment less hospitable to Lactobacillus species.
  • Vaginal microbiome shifts from Lactobacillus-dominant communities to diverse anaerobic flora. Postmenopausal women have low-Lactobacillus communities at approximately 50% of visits, compared with ~21% in premenopausal women. Lactobacillus-dominated communities are associated with lower odds of vaginal atrophy and dryness.[8][9]
  • Urethral and bladder epithelium contain estrogen receptors and undergo atrophic changes, contributing to urinary frequency, urgency, dysuria, and recurrent UTI.[10]
  • Estrogen receptors (ERα and ERβ) are present throughout the vagina, urethra, bladder trigone, and pelvic floor musculature, explaining the broad symptom profile.[7][9]

Clinical presentation​

Symptoms span three domains:[6][4][2]

  • Genital: vaginal dryness, burning, itching, irritation, vaginal discharge, introital narrowing
  • Sexual: dyspareunia, decreased lubrication, post-coital bleeding
  • Urinary: urgency, frequency, dysuria, nocturia, recurrent urinary tract infections

Patients often do not volunteer these symptoms spontaneously; proactive screening is recommended at clinical encounters.[6][1]

Diagnosis​

Diagnosis is clinical, based on symptoms with or without physical findings, after ruling out other etiologies.[6][10]

  • Examination findings: thin, pale, or erythematous vulvar/vaginal epithelium; loss of rugae; introital narrowing; decreased tissue elasticity; urethral caruncle; resorption of labia minora
  • Vaginal pH >4.5 in untreated postmenopausal patients supports the diagnosis
  • Routine biopsy is unnecessary for uncomplicated GSM; suspicious focal lesions, persistent unexplained symptoms, or bleeding require evaluation for other diagnoses and biopsy when indicated.
  • No consensus exists on the number or type of symptoms needed for formal diagnosis[10]

Management​

The 2025 AUA/SUFU/AUGS Guideline and the 2020 NAMS Position Statement provide management frameworks.[10][3] Treatment is guided by symptom severity, goals, contraindications, and patient preference; a mandatory failure of nonhormonal treatment is not required for every patient before considering local low-dose estrogen.

Nonhormonal options, alone or with other treatment​

  • Vaginal moisturizers (polycarbophil-based, hyaluronic acid) used 1–3 times per week[6][3][11]
  • Vaginal lubricants (water-, silicone-, or oil-based) used during intercourse[3][11]
  • Avoidance of vulvar irritants[6]

Local estrogen and other prescription options​

Low-dose vaginal estrogen is the gold standard and has the most robust evidence base.[1][10][3]

Creams, inserts, and the low-dose estradiol ring offer different application and cost options. Absorption depends on the product, dose, and tissue state; no formulation has demonstrated superior breast-cancer safety. Use the estrogen pharmacology hub for product-specific dosing and precautions rather than substituting one formulation's schedule for another.

A 2024 systematic review in the Annals of Internal Medicine confirmed that vaginal estrogen, vaginal DHEA (prasterone), oral ospemifene, and vaginal moisturizers may all improve some GSM symptoms in the short term, though long-term comparative effectiveness data remain limited.[12]

Alternative pharmacologic agents (detailed in the pharmacology hub — see cross-references below):

  • Vaginal DHEA (prasterone / Intrarosa): FDA-approved for moderate to severe dyspareunia due to menopausal vulvovaginal atrophy. Its label warns about current or past breast cancer; conversion to estrogen and limited survivor data preclude assurances of safety during aromatase-inhibitor treatment.[19]
  • Ospemifene (Osphena): Oral SERM approved for moderate to severe dyspareunia or vaginal dryness due to menopausal vulvovaginal atrophy. It is not an approved OAB/UUI treatment. Review endometrial and thromboembolic warnings; its US label advises against use in patients with known, suspected, or previous breast cancer.[21]

AUA guidance does not recommend routine endometrial surveillance solely because a patient uses local low-dose vaginal estrogen, vaginal DHEA, or ospemifene. Any postmenopausal bleeding still warrants evaluation; see endometrial evaluation.[10]

Adjunctive therapies​

Energy-based therapies (laser and radiofrequency)​

Fractional CO₂ laser and erbium:YAG laser have been studied for GSM. A 2025 systematic review found that CO₂ laser compared with sham showed little to no difference in dyspareunia, dysuria, or quality of life (low certainty of evidence), and similarly showed no significant difference compared with vaginal estrogen.[14] A meta-analysis found no statistically significant differences between laser and vaginal estrogen on several outcomes, with important heterogeneity; this does not establish equivalence.[15] The NAMS 2020 position statement concluded there are insufficient placebo-controlled trials to make treatment recommendations for energy-based therapies.[3] The 2025 AUA/SUFU/AUGS guideline states that evidence does not support routine use for GSM symptoms; treatment outside trials remains experimental.[10]

For the dedicated cross-indication review (GSM, SUI, lichen sclerosus, vaginal laxity, breast-cancer-survivor data, FDA / ACOG / AUA / ESSM positions), see Vaginal Laser Therapy.

Special population: breast cancer survivors​

  • Nonhormonal methods are first-line for patients with a history of estrogen-dependent breast cancer.[16]
  • If nonhormonal treatments fail, low-dose vaginal estrogen may be used after shared decision-making, including patients on tamoxifen. For patients on aromatase inhibitors, shared decision-making among patient, gynecologist, and oncologist is recommended.[16]
  • A 2025 meta-analysis pooled eight observational studies. Recurrence analysis included 24,060 patients (unadjusted OR 0.48; 95% CI 0.23–0.98); separate mortality analyses also found no increase. Confounding and treatment selection limit these associations: they do not demonstrate protection or exclude risk in every subgroup. AUA highlights an increased recurrence association in the Danish cohort's concurrent AI subgroup, supporting particular caution and oncology involvement during AI treatment.[17][10]
  • A 2026 review discusses low-dose vaginal estrogen absorption and oncologic outcomes.[18] FDA label changes occurred through product-specific approvals beginning in February 2026; see the regulatory update in the estrogen hub.
  • Lower-dose inserts or the low-dose estradiol ring may be considered to limit systemic exposure, with formulation choice agreed with the oncology team. This pharmacokinetic rationale does not establish an oncologically safest product.[10]

VEMORA (July 2026): symptom benefit is not proof of oncologic safety. This open-label RCT randomized 23 aromatase-inhibitor users to vaginal estrogen or moisturizer for 24 weeks. Estrogen improved dryness and dyspareunia more; two late estradiol elevations occurred in participants reporting AI nonadherence. The study was too small and short to establish breast-cancer recurrence safety. Continue oncology-informed shared decision-making, especially during AI therapy.[20]

See Also​

  • Vaginal & Topical Estrogen — formulation pharmacology, systemic absorption, breast-cancer counseling, product-specific FDA updates, and the July 2026 TAPER application trial.
  • Vaginal DHEA (Prasterone) — approved indication, hormone metabolism, and breast-cancer safety limitations.
  • Ospemifene — oral SERM for menopausal dryness/dyspareunia, endometrial and VTE risks, and drug interactions.
  • Recurrent UTI — vaginal estrogen as first-line in postmenopausal patients (AUA/CUA/SUFU 2025 framework and contemporary prevention evidence).
  • Preoperative Hormonal Priming — IMPROVE trial; role of local estrogen before pelvic floor surgery.

References​

1. Faubion SS, Sood R, Kapoor E. "Genitourinary Syndrome of Menopause: Management Strategies for the Clinician." Mayo Clin Proc. 2017;92(12):1842–1849. doi:10.1016/j.mayocp.2017.08.019

2. Crandall CJ, Mehta JM, Manson JE. "Management of Menopausal Symptoms: A Review." JAMA. 2023;329(5):405–420. doi:10.1001/jama.2022.24140

3. North American Menopause Society. "The 2020 Genitourinary Syndrome of Menopause Position Statement of the North American Menopause Society." Menopause. 2020;27(9):976–992. doi:10.1097/GME.0000000000001609

4. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Gynecology. "Female Sexual Dysfunction: ACOG Practice Bulletin, Number 213." Obstet Gynecol. 2019;134(1):e1–e18. doi:10.1097/AOG.0000000000003324

5. Phillips NA, Bachmann GA. "The Genitourinary Syndrome of Menopause." Menopause. 2021;28(5):579–588. doi:10.1097/GME.0000000000001728

6. Ringel NE, Iglesia C. "Common Benign Chronic Vulvar Disorders." Am Fam Physician. 2020;102(9):550–557.

7. Szymański JK, Słabuszewska-Józwiak A, Jakiel G. "Vaginal Aging — What We Know and What We Do Not Know." Int J Environ Res Public Health. 2021;18(9):4935. doi:10.3390/ijerph18094935

8. Shardell M, Gravitt PE, Burke AE, Ravel J, Brotman RM. "Association of Vaginal Microbiota With Signs and Symptoms of the Genitourinary Syndrome of Menopause Across Reproductive Stages." J Gerontol A Biol Sci Med Sci. 2021;76(9):1542–1550. doi:10.1093/gerona/glab120

9. Qi W, Li H, Wang C, et al. "The Effect of Pathophysiological Changes in the Vaginal Milieu on the Signs and Symptoms of Genitourinary Syndrome of Menopause (GSM)." Menopause. 2020;28(1):102–108. doi:10.1097/GME.0000000000001644

10. Kaufman MR, Ackerman AL, Amin KA, et al. "The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause." J Urol. 2025. doi:10.1097/JU.0000000000004589

11. Chang JG, Lewis MN, Wertz MC. "Managing Menopausal Symptoms: Common Questions and Answers." Am Fam Physician. 2023;108(1):28–39.

12. Danan ER, Sowerby C, Ullman KE, et al. "Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause: A Systematic Review." Ann Intern Med. 2024;177(10):1400–1414. doi:10.7326/ANNALS-24-00610

13. Steinman MA. "Alternative Treatments to Selected Medications in the 2023 American Geriatrics Society Beers Criteria®." J Am Geriatr Soc. 2025;73(9):2657–2677. doi:10.1111/jgs.19500

14. Zerzan NL, Greer N, Ullman KE, et al. "Energy-Based Interventions for Genitourinary Syndrome of Menopause: A Systematic Review of Randomized Controlled Trials and Prospective Observational Studies." Menopause. 2025;32(2):176–183. doi:10.1097/GME.0000000000002465

15. Jang YC, Leung CY, Huang HL. "Comparison of Severity of Genitourinary Syndrome of Menopause Symptoms After Carbon Dioxide Laser vs Vaginal Estrogen Therapy: A Systematic Review and Meta-analysis." JAMA Netw Open. 2022;5(9):e2232563. doi:10.1001/jamanetworkopen.2022.32563

16. American College of Obstetricians and Gynecologists. "Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-Dependent Breast Cancer: Clinical Consensus." Obstet Gynecol. 2021;138(6):950–960. doi:10.1097/AOG.0000000000004601

17. Beste ME, Kaunitz AM, McKinney JA, Sanchez-Ramos L. "Vaginal Estrogen Use in Breast Cancer Survivors: A Systematic Review and Meta-Analysis of Recurrence and Mortality Risks." Am J Obstet Gynecol. 2025;232(3):262–270.e1. doi:10.1016/j.ajog.2024.10.054

18. Mainar LB, Nieto-Pascual L, Bravo EI, et al. "Safety of Vaginal Estrogen in Breast Cancer Survivors: Current Evidence on Systemic Absorption and Oncologic Outcomes." Maturitas. 2026;208:108914. doi:10.1016/j.maturitas.2026.108914

19. INTRAROSA (prasterone). US prescribing information, revised January 2026. DailyMed label.

20. Niravath P, Rimawi M, Sun K, et al. "VEMORA: Vaginal Estrogen versus non-hormonal MOisturizer in women Receiving Aromatase inhibitors: a randomized, controlled trial." Breast Cancer Res Treat. 2026;218(2):25. doi:10.1007/s10549-026-08025-0

21. OSPHENA (ospemifene). US prescribing information. DailyMed label.